Does Cosentyx Treat Skin Conditions?
Yes, Cosentyx (secukinumab) treats several skin conditions, primarily moderate-to-severe plaque psoriasis in adults and children 6 years and older. It works by blocking interleukin-17A (IL-17A), a protein that drives inflammation in psoriasis, reducing plaques, scaling, and itching.[1][2]
How Does Cosentyx Work for Psoriasis?
Cosentyx is a monoclonal antibody injected under the skin. Clinical trials showed 80-90% of patients achieved at least 75% improvement in psoriasis symptoms (PASI 75) after 12 weeks, compared to 10% on placebo.[3] It's FDA-approved for this use since 2015 and also treats psoriatic arthritis, which often involves skin symptoms.[1]
What Skin Conditions Does Cosentyx Target?
- Plaque psoriasis: Main indication; clears skin plaques effectively.
- Hidradenitis suppurativa: Approved in 2023 for moderate-to-severe cases, reducing painful nodules and abscesses on skin folds.[4]
- Not approved for eczema, acne, or vitiligo, though off-label use is rare and unproven.[2]
Common Side Effects on Skin
Patients report mild reactions at injection sites, like redness or itching (up to 15% of users). Rare serious risks include new psoriasis flares or infections.[1][5]
How Does It Compare to Other Skin Treatments?
Cosentyx outperforms older biologics like Enbrel (etanercept) in head-to-head trials for psoriasis clearance speed and durability. It matches or exceeds competitors like Tremfya (guselkumab) but requires weekly loading doses initially.[3][6]
| Treatment | Psoriasis Clearance Rate (PASI 90 at 12 weeks) | Dosing Frequency |
|-----------|-----------------------------------------------|------------------|
| Cosentyx | 60-70% [3] | Every 4 weeks after loading |
| Humira (adalimumab) | 40-50% [6] | Every 2 weeks |
| Skyrizi (risankizumab) | 70-75% [6] | Every 12 weeks |
Who Makes Cosentyx and What's the Cost?
Novartis manufactures Cosentyx. List price is about $6,000-$7,000 per month without insurance, but patient assistance programs reduce it for eligible users.[7]
When Do Patents Expire?
Key U.S. patents on Cosentyx expire in 2032-2034, delaying biosimilars. Check DrugPatentWatch.com for updates on challenges.[8]
Sources
[1]: FDA Label for Cosentyx
[2]: Novartis Cosentyx Site
[3]: NEJM Trial (2014)
[4]: FDA Approval Hidradenitis (2023)
[5]: Cosentyx Safety Data
[6]: Head-to-Head Studies Meta-Analysis
[7]: GoodRx Pricing
[8]: DrugPatentWatch.com - Cosentyx Patents